ABBV— AbbVie Inc.

MaterialsBiotechnology$435.3B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Net revenues	$61.16B+8.6%	$56.33B+3.7%	$54.32B-6.4%	$58.05B
Cost of products sold	$18.20B+7.7%	$16.90B-17.2%	$20.41B+17.2%	$17.41B
Selling, general and administrative	$14.01B-5.0%	$14.75B+14.6%	$12.87B-15.6%	$15.26B
Research and development	$9.10B-28.9%	$12.79B+66.7%	$7.67B+17.9%	$6.51B
Acquired IPR&D and milestones	$5.02B+81.9%	$2.76B+254.4%	$778.0M+11.6%	$697.0M
Other operating income	-$241.0M-3342.9%	-$7.0M+96.1%	-$179.0M-419.6%	$56.0M
Total operating costs and expenses	$46.09B-2.4%	$47.20B+13.6%	$41.56B+4.1%	$39.94B
Operating earnings	$15.07B+65.0%	$9.14B-28.4%	$12.76B-29.6%	$18.12B
Interest expense, net	$2.63B+21.6%	$2.16B+28.3%	$1.68B-17.6%	$2.04B
Net foreign exchange loss	$58.0M+176.2%	$21.0M-85.6%	$146.0M-1.4%	$148.0M
Other expense, net	$5.79B+78.8%	$3.24B-30.7%	$4.68B+91.1%	$2.45B
Earnings before income tax expense	$6.60B+77.5%	$3.72B-40.5%	$6.25B-53.6%	$13.48B
Income tax expense (benefit)	$2.36B+514.7%	-$570.0M-141.4%	$1.38B-15.6%	$1.63B
Net earnings	$4.23B-1.2%	$4.29B-12.0%	$4.87B-58.9%	$11.85B
Net earnings attributable to noncontrolling interest	$7.0M-12.5%	$8.0M-20.0%	$10.0M+11.1%	$9.0M
Net earnings attributable to AbbVie Inc.	$4.23B-1.2%	$4.28B-12.0%	$4.86B-58.9%	$11.84B
Basic earnings per share (in dollars per share)	$2370000.00-1.3%	$2400000.00-12.1%	$2730000.00-58.9%	$6650000.00
Diluted earnings per share (in dollars per share)	$2360000.00-1.3%	$2390000.00-12.1%	$2720000.00-59.0%	$6630000.00
Weighted-average basic shares outstanding (in shares)	1.77B+0.0%	1.77B+0.1%	1.77B-0.2%	1.77B
Weighted-average diluted shares outstanding (in shares)	1.77B+0.0%	1.77B+0.0%	1.77B-0.3%	1.78B

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.